Trimeris, Roche Withdraw Supplemental Application To Market Needle-Free Device With Antiretroviral Fuzeon
Main Category: HIV / AIDSAlso Included In: Pharma Industry / Biotech Industry
Article Date: 09 Oct 2007 - 11:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
Durham, N.C.-based pharmaceutical company Trimeris and Swiss pharmaceutical company Roche on Wednesday announced they are withdrawing a supplemental application with FDA to sell a needle-free injection device for use with the HIV antiretroviral drug Fuzeon, the Raleigh News & Observer reports (Vollmer, Raleigh News & Observer, 10/4).
Trimeris and Roche in July 2005 applied to use Bioject Medical Technologies' Biojector 2000 injection system as a needle-free injection device for use with Fuzeon, which is currently administered with a needle. Fuzeon, a fusion inhibitor, is approved to treat HIV infection in combination with other antiretrovirals. About 10% of eligible U.S. HIV-positive patients were taking Fuzeon in 2005 (Kaiser Daily HIV/AIDS Report, 11/2/05).
The companies said they decided to withdraw the application after an assessment of the clinical program, as well as a delay in FDA approval because of a request to produce more data, the AP/Houston Chronicle reports (AP/Houston Chronicle, 10/3). "While the device has shown potential benefit for some patients, we don't believe it's the ideal alternative delivery option for all treatment-experienced patients," Michelle Zupancic, a vice president at Roche, said, adding, "We continue to review other options for administering Fuzeon," (Trimeris release, 10/3).
The companies also said in a statement that they believe that "patients who are currently administering Fuzeon with the device through an existing program or clinical trial may continue to do so, provided that the precautions in the current Fuzeon label regarding use with B2000 are followed" (AP/Houston Chronicle, 10/3).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our hiv / aids section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/84808.php>
APA
http://www.medicalnewstoday.com/releases/84808.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




